This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Bob Dubridge
EVP of Research at Maverick Therapeutics


Bob received his B.A. in Biology from the University of California at San Diego and his Ph.D. in Genetics from Stanford University. After completing his postdoctoral studies at Genentech, Bob was one of the founding scientists of Cell Genesys, Inc. He went on to become the Director of the Massively Parallel Signature Sequencing (MPSS) project at Lynx Therapeutics and his group was responsible for setting up the first next generation sequencing platform. From 1999 to 2010 Bob led the New Technologies and Antibody Engineering groups at Eos and then PDL Biopharma. In 2010 he founded Full Spectrum Genetics (FSG) to develop a novel, high throughput mutation profiling system to create detailed structural maps of protein binding sites using single substitution libraries. He joined Maverick at its formation to develop a novel class of conditionally activated T-cell engagers in 2017.

Agenda Sessions

  • COBRA – A Novel Class of Conditionally Active, T-cell Engaging Bispecifics for the Treatment of Solid Tumors